How can we improve accessibility for cancer drugs?

Tine Geldof

Tine Geldof

What was my dream when I was little?

My childhood dream was absolutely to become a mad scientist, such that I could make potions to obtain super-national powers and make a machine to time-travel.

What am I doing when I am not working on my PhD?

As a real movie lover, I find it relaxing to watch movies or shows in the evening.
An evening out to the movies is therefore one of my favourite pastimes. Also, as a physicist, keeping myself informed by the latest news in astrophysics is a real interest of mine.

What is my PhD about?

The aim of my PhD research is to expedite patient access to new and expensive but essential drugs and maximize societal value and manufacturers’ return on investment of these innovative medicines. I also want to enable the expansion of these theoretical frameworks and practically oriented models to other domains in the processing industry.

Why is this important for practice?

My research will develop a tool, a prototype of an expert system, to help stakeholders in making decisions during the development and market-access process of drugs.

How do I like to be remembered after my PhD?

As the researcher who helped in changing the development process of innovative drugs to be more efficient, ultimately helping patients in need for the drugs, for whom time is relevant, by increasing access. My ultimate ambition is to be able to get some movement into the Belgian, and European, healthcare systems.

Roche Pharmaceuticals

What convinced you to take part in this PhD research?

As an innovative company, we want to address the current challenges to bring medical innovation to patients. We want to tackle this challenge together with Vlerick Business School by supporting this PhD research. The project aims to contribute to the acceleration of drug development and market access for patients and hence evolve the access system.

Why is this research relevant to your company?

This research project is very important for Roche. We believe that new ways of reimbursement will contribute to the sustainability of the healthcare system and that the collection of real world evidence data, which is the common thread in this project, will play a key role in this.

& Rankings

Equis Association of MBAs AACSB Financial Times